Hi
One Million Microdoses of LSD could potentially treat 16,000 patients with depression for 6 months!
And this is what it looks like……..
I recently visited the manufacturer in Canada which is fully licensed by the Canadian Government to manufacture GMP-grade LSD for the pharmaceutical industry.
At the time of the visit, the manufacturer had just produced the LSD that would be shipped to MindBio for its Phase 2 Clinical Trials.
The GMP-grade LSD seen in these jars is used to create a novel sublingual formulation for LSD-microdosing that allows patients to titrate their microdose. The formulation has a long shelf life and is designed to be stored and used at home.
Through a secure chain of custody, MindBio is pleased to announce the GMP LSD has safely and securely arrived at our labs for processing in preparation for both Phase 2 Clinical Trials.
By using microdosing, we are creating a unique treatment model that is globally scalable, accessible, and affordable, aiming to address the existing challenges in mental health care.
MindBio is amassing the world’s largest repository of biometric, physiological and psychometric data from Microdosing randomised controlled clinical trials in a big data play for the Company.
We are leading the world in LSD-Microdosing and look forward to providing the next update to shareholders soon.
We invite you to join us in support of creating a brighter future for mental health.
Stay well!
Justin Hanka
Cofounder and Chief Executive
Receive our latest updates here:
https://www.mindbiotherapeutics.com/get-updates
Follow MindBio on LinkedIn:
https://www.linkedin.com/company/mindbio-therapeutics/?viewAsMember=true
Follow CEO Justin Hanka on LinkedIn:
0 comments